Fluorescence PCR · Pharmacogenetics
Human CYP2C9 and VKORC1 Gene Polymorphism Detection Kit (Fluorescence PCR)
Qualitatively detects CYP2C9*3 (rs1057910, 1075A>C) and VKORC1 (rs9923231, -1639G>A) polymorphisms in genomic DNA from human whole blood. Used for pharmacogenetic assessment, such as warfarin sensitivity.
- SKU Code
AENE-GE014A- Approval
- On request
- Product Type
- Assay / Kit
- Status
- Available
Qualitatively detects CYP2C9*3 (rs1057910, 1075A>C) and VKORC1 (rs9923231, -1639G>A) polymorphisms in genomic DNA from human whole blood. Used for pharmacogenetic assessment, such as warfarin sensitivity.
| Product type | Assay / Kit |
|---|---|
| Technology platform | Fluorescence PCR |
| Application area | Pharmacogenetics |
Certificate
CE/TFDA
Epidemiology
Warfarin is an oral anticoagulant widely employed in clinical settings for the prophylaxis and management of thromboembolic conditions. It possesses a narrow therapeutic index and displays substantial inter-ethnic and inter-individual variability. Data reveal that the stable dose requirement can differ by more than 20-fold between patients. Annually, 15.2% of patients on warfarin experience bleeding adverse events, with 3.5% developing fatal hemorrhages. Pharmacogenetic research indicates that polymorphisms in the warfarin target enzyme VKORC1 and the metabolizing enzyme CYP2C9 significantly contribute to dose variation. Warfarin acts by specifically inhibiting vitamin K epoxide reductase (VKORC1), thereby blocking vitamin K-dependent clotting factor synthesis and exerting its anticoagulant effect. Numerous studies highlight that VKORC1 promoter polymorphisms are the primary determinants of racial and individual differences in warfarin dosage requirements. Warfarin is metabolized by CYP2C9, and mutations in this gene markedly slow drug metabolism. Consequently, patients on warfarin face a heightened risk of bleeding during the initial phase of therapy, estimated to be two to three times greater.
Work Flow
The advised extraction reagents consist of a viral DNA/RNA purification kit along with an automated nucleic acid extraction instrument.
| SKU code | AENE-GE014A |
|---|---|
| Storage | Liquid: ≤-18℃ |
| Shelf-life | 12 months |
| Specimen Type | Fresh EDTA anticoagulated blood |
| CV | ≤5.0% |
| LoD | 1.0ng/μL |
| Specificity | There is no cross-reactivity with other highly consistent sequence of human genome (human CYP2C19 gene, human RPN2 gene); mutation of CYP2C9*13 and VKORC1 (3730G A) outside the detection range of this kit |
| Applicable Instruments | Applied Biosystems 7500 Real-Time PCR Systems Applied Biosystems 7500 Fast Real-Time PCR Systems QuantStudio®5 Real-Time PCR Systems SLAN-96P Real-Time PCR Systems LightCycler®480 Real-Time PCR system LineGene 9600 Plus Real-Time PCR Detection System MA-6000 Real-Time Quantitative Thermal Cycler BioRad CFX96 Real-Time PCR System BioRad CFX Opus 96 Real-Time PCR System |
| Approval | On request |
|---|---|
| Documents | Datasheet, IFU, SDS, COA / conformance, origin, and export documents where available |
FAQ
What should be confirmed before quotation?
Sample context, collection method, and extraction workflow should be confirmed before final kit selection.
Which documents can be requested?
Datasheet, IFU, SDS, COA / conformance, origin, insurance, and export documents can be checked where available.
Can the format be adjusted for different workflows?
Liquid or lyophilized format options should be confirmed together with instrument compatibility and shipment requirements.
Inquiry
Send the essentials for a useful first reply.
Share the application, sample type, format, destination, and expected quantity so AeneBio can route AENE-GE014A to the right quote or sample discussion.